Healthcare
Exclusive insider sentiment analysis for the Healthcare sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-21 23:52 | 2026-07-17 | BFLY | Butterfly Network, Inc. | ROTHBERG JONATHAN M | Director, 10% owner | Medical Devices | SALE | $6.64 | 3,126,453 | $20,748,393 | 496,680 | -86.3% |
| 2026-07-21 23:38 | 2026-07-17 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $2.44 | 4,863 | $11,866 | 2,858,935 | +0.2% |
| 2026-07-21 23:24 | 2026-03-27 | RANI | Rani Therapeutics Holdings, Inc. | Javadi Alireza | Officer; Chief Technical Officer | Biotechnology | SALE | $0.78 | 386 | $301 | 9,689 | -3.8% |
| 2026-07-21 23:04 | 2026-07-17 | CV | CapsoVision, Inc | HARARI ELIYAHOU ET AL | 10% owner | Medical Devices | BUY | $6.73 | 61,068 | $410,988 | 3,343,119 | +1.9% |
| 2026-07-21 22:29 | 2026-07-17 | RANI | Rani Therapeutics Holdings, Inc. | Imran Talat | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $0.72 | 35,000 | $25,193 | 469,736 | +8.1% |
| 2026-07-21 22:25 | 2024-12-27 | RANI | Rani Therapeutics Holdings, Inc. | Imran Talat | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $1.41 | 8,014 | $11,300 | 486,737 | -1.6% |
| 2026-07-21 22:13 | 2026-07-20 | MLTX | MoonLake Immunotherapeutics | Reich Kristian | Officer; Chief Scientific Officer | Biotechnology | SALE | $20.09 | 43,700 | $877,933 | 2,764,746 | -1.6% |
| 2026-07-21 21:23 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Collins Helen Louise | Officer; CHIEF MEDICAL OFFICER | Biotechnology | OPT+S | $52.67 | 5,000 | $263,374 | 25,000 | -16.7% |
| 2026-07-21 21:24 | 2026-07-17 | ELVN | Enliven Therapeutics, Inc. | Hohl Benjamin | Officer; CHIEF FINANCIAL OFFICER | Biotechnology | OPT+S | $52.64 | 6,018 | $316,780 | 46,054 | -11.6% |
| 2026-07-21 21:27 | 2026-07-20 | JNJ | JOHNSON & JOHNSON | Broadhurst Vanessa | Officer; EVP, Global Corp Affairs | Drug Manufacturers - General | OPT+S | $251.27 | 23,054 | $5,792,686 | 23,003 | -50.1% |
| 2026-07-21 20:54 | 2026-07-16 | VOR | Vor Biopharma Inc. | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Biotechnology | SALE | $19.75 | 213 | $4,207 | 4,501,882 | 0.0% |
| 2026-07-21 20:58 | 2026-07-20 | DXCM | DEXCOM INC | SAYER KEVIN R | Director, Officer; Executive Chair | Medical Devices | SALE | $76.32 | 26,756 | $2,041,999 | 328,970 | -7.5% |
| 2026-07-21 20:35 | 2026-07-20 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $531.69 | 9,500 | $5,051,035 | 324,443 | -2.8% |
| 2026-07-21 20:15 | 2026-07-20 | IMNN | Imunon, Inc. | Eylward Susan | Officer; General Counsel and Corp Sec | Biotechnology | SALE | $1.78 | 2,150 | $3,830 | 2,896 | -42.6% |
| 2026-07-21 20:21 | 2026-07-20 | BFLY | Butterfly Network, Inc. | DEVIVO JOSEPH | Director, Officer; President & CEO | Medical Devices | SALE | $6.56 | 211,798 | $1,389,395 | 7,672,046 | -2.7% |
| 2026-07-21 20:23 | 2026-07-20 | BFLY | Butterfly Network, Inc. | Doherty John N. | Officer; EVP, CFO | Medical Devices | SALE | $6.56 | 57,136 | $374,812 | 1,397,276 | -3.9% |
| 2026-07-21 20:26 | 2026-07-20 | BFLY | Butterfly Network, Inc. | Ku Victor | Officer; Chief Technology Officer | Medical Devices | SALE | $6.56 | 48,540 | $318,422 | 1,015,099 | -4.6% |
| 2026-07-21 20:26 | 2026-07-16 | GKOS | GLAUKOS Corp | Thurman Alex R. | Officer; SVP & CHIEF FINANCIAL OFFICER | Medical Devices | OPT+S | $160.00 | 10,000 | $1,600,000 | 43,906 | -18.6% |
| 2026-07-21 14:23 | 2026-07-20 | ANIX | Anixa Biosciences Inc | KUMAR AMIT | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $3.46 | 5,000 | $17,300 | 640,812 | +0.8% |
| 2026-07-21 12:00 | 2026-07-17 | PRQR | ProQR Therapeutics N.V. | Filius Bart | Director | Biotechnology | BUY | $1.72 | 150,000 | $257,925 | 300,000 | +100.0% |
| 2026-07-21 01:47 | 2026-07-16 | IMA | ImageneBio, Inc. | Lally Robert B | Officer; Principal Accounting Officer | Biotechnology | SALE | $5.42 | 3,196 | $17,334 | 55,582 | -5.4% |
| 2026-07-21 01:16 | 2026-07-20 | MDGL | MADRIGAL PHARMACEUTICALS, INC. | Sibold William John | Director, Officer; President and CEO | Biotechnology | OPT+S | $547.30 | 2,500 | $1,368,254 | 209,329 | -1.2% |
| 2026-07-21 01:00 | 2026-07-17 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer; Chief Medical Officer | Biotechnology | OPT+S | $26.53 | 416 | $11,036 | 51,384 | -0.8% |
| 2026-07-21 01:10 | 2026-07-16 | FULC | Fulcrum Therapeutics, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $3.55 | 167,616 | $594,668 | 7,080,945 | +2.4% |
| 2026-07-20 23:38 | 2026-07-16 | BLLN | BillionToOne, Inc. | Johnson Nancy JoAnn | Officer; See Remarks | Diagnostics & Research | SALE | $128.29 | 14,199 | $1,821,628 | 6,900 | -67.3% |
| 2026-07-20 23:19 | 2026-07-16 | ADPT | Adaptive Biotechnologies Corp | BOBULSKY SUSAN | Officer; Chief Commercial Officer, MRD | Biotechnology | SALE | $23.00 | 5,000 | $115,000 | 401,288 | -1.2% |
| 2026-07-20 22:19 | 2026-07-20 | ANIX | Anixa Biosciences Inc | Titterton Lewis H jr | Director | Biotechnology | BUY | $3.47 | 12,000 | $41,640 | 986,967 | +1.2% |
| 2026-07-20 22:08 | 2026-07-16 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Biotechnology | BUY | $8.93 | 160,354 | $1,432,122 | 16,977,927 | +1.0% |
| 2026-07-20 21:48 | 2026-07-20 | CLOV | CLOVER HEALTH INVESTMENTS, CORP. /DE | Soares Karen | Officer; Chief Legal Officer | Healthcare Plans | SALE | $4.51 | 51,700 | $233,167 | 1,505,522 | -3.3% |
| 2026-07-20 21:30 | 2026-07-16 | CBIO | CRESCENT BIOPHARMA, INC. | Fairmount Funds Management LLC | Director, 10% owner | Biotechnology | BUY | $14.50 | 853,450 | $12,375,025 | 3,601,316 | +31.1% |
| 2026-07-20 21:34 | 2026-07-17 | AKTS | Aktis Oncology, Inc. | Herrmann Ken | Director | Biotechnology | OPT+S | $25.21 | 3,065 | $77,259 | 0 | -100.0% |
| 2026-07-20 21:00 | 2026-07-17 | DNA | Ginkgo Bioworks Holdings, Inc. | Coen Steven P. | Officer; See remarks | Biotechnology | OPT+S | $7.90 | 752 | $5,943 | 51,438 | -1.4% |
| 2026-07-20 21:03 | 2026-07-16 | CERS | CERUS CORP | Jayaraman Vivek K | Officer; Chief Executive Officer | Medical Devices | SALE | $3.16 | 16,666 | $52,665 | 2,232,211 | -0.7% |
| 2026-07-20 20:30 | 2026-07-17 | HIMS | Hims & Hers Health, Inc. | Okupe Oluyemi | Officer; Chief Financial Officer | Drug Manufacturers - Specialty & Generic | OPT+S | $31.99 | 7,163 | $229,168 | 284,321 | -2.5% |
| 2026-07-20 20:32 | 2026-07-17 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $537.05 | 9,500 | $5,101,940 | 324,443 | -2.8% |
| 2026-07-20 20:16 | 2026-07-17 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biotechnology | BUY | $0.83 | 500 | $415 | 368,885 | +0.1% |
| 2026-07-20 20:26 | 2026-07-16 | VEEV | VEEVA SYSTEMS INC | Schwenger Thomas D. | Officer; Pres. & Chief Customer Officer | Health Information Services | SALE | $200.00 | 5,000 | $1,000,000 | 20,449 | -19.6% |
| 2026-07-20 20:09 | 2026-07-16 | INCY | INCYTE CORP | Issa Mohamed Khairie | Officer; EVP, Head of U.S. Commercial | Biotechnology | SALE | $115.01 | 1,093 | $125,706 | 63,940 | -1.7% |
| 2026-07-20 20:10 | 2026-07-16 | INCY | INCYTE CORP | Stein Steven H | Officer; CMO & Head of Late-Stage Dev. | Biotechnology | SALE | $114.73 | 1,877 | $215,348 | 21,118 | -8.2% |
| 2026-07-20 18:55 | 2026-07-17 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Biotechnology | SALE | $13.70 | 10 | $137 | 2,857,480 | 0.0% |
| 2026-07-20 14:15 | 2026-07-15 | DOCS | Doximity, Inc. | Sitaram Siddharth | Officer; Chief Accounting Officer | Health Information Services | OPT+S | $22.02 | 1,732 | $38,139 | 93,774 | -1.8% |
| 2026-07-20 10:00 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Kreitzer Anatol | Officer; Chief Discovery Officer | Biotechnology | SALE | $37.09 | 36,284 | $1,345,893 | 174,906 | -17.2% |
| 2026-07-20 10:00 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | GILLIS JONATHAN | Officer; CAO and Interim CFO | Biotechnology | SALE | $37.12 | 36,979 | $1,372,668 | 144,240 | -20.4% |
| 2026-07-20 10:07 | 2026-07-15 | MLTX | MoonLake Immunotherapeutics | Reich Kristian | Officer; Chief Scientific Officer | Biotechnology | SALE | $20.01 | 16,105 | $322,261 | 2,808,446 | -0.6% |
| 2026-07-17 20:01 | 2026-07-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | Biotechnology | OPT+S | $26.91 | 4,730 | $127,284 | 37,109 | -11.3% |
| 2026-07-17 20:15 | 2026-07-15 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | Biotechnology | OPT+S | $71.17 | 1,000 | $71,170 | 0 | -100.0% |
| 2026-07-18 01:43 | 2026-07-17 | MNKD | MANNKIND CORP | Thomson David | Officer; EVP Genl Counsel & Secretary | Biotechnology | OPT+S | $4.05 | 24,109 | $97,641 | 797,554 | -2.9% |
| 2026-07-18 01:44 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Hanson Kristopher | Officer; General Counsel | Biotechnology | SALE | $36.82 | 16,508 | $607,871 | 145,823 | -10.2% |
| 2026-07-18 01:45 | 2026-07-16 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Biotechnology | SALE | $13.73 | 10 | $137 | 2,857,490 | 0.0% |
| 2026-07-18 01:45 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Lillie James Woodruff | Officer; Chief Scientific Officer | Biotechnology | SALE | $36.88 | 18,267 | $673,636 | 224,462 | -7.5% |
Strategic Analysis
Analyzing insider transactions within the Healthcare sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.